Arvinas (ARVN) Q2 FY26 earnings call

Arvinas achieved a significant milestone with the FDA approval of VEPPANU, the first PROTAC degrader, and subsequently out-licensed it, generating substantial revenue. The company is strategically focusing its pipeline on oncology and neurology, advancing several Phase I programs with upcoming data catalysts. While regulatory delays impacted the LRRK2 program, Arvinas maintains a strong financial position to fund operations through key milestones into the second half of 2028.